Steadiwear Innovating Tremor Treatment
Those who suffer from Parkinson's disease or have a loved one who is living with it understand first-hand how it visibly affects their quality of life. Tremors can make minor tasks such as tying your shoes or drinking a cup of coffee seems almost impossible. Since there is currently no cure for Parkinson’s, patients are left with several options to treat their signs and symptoms. Everything from invasive brain surgery to medications; exercise or even botox. Although it may seem that there are abundant treatment paths for patient exploration, not all paths are suited for all Parkinson’s patients.
Northern Biologics Announces Exciting New CEO
Northern Biologics, the relatively young organization that specializes in intelligent immune-oncology products, acquired some impressive new leadership this past month. “Dr. Vickers is a preeminent R&D leader with more than two decades of experience in the biotech and pharmaceutical industry” Philip Vickers was announced as the new CEO on November 9th. Vickers joins Northern Biologics from the Executive Committee for Shire where he was the head of Research & Development.
BresoDx completes MaRS EXCITE program: at-home sleep apnea device available to Ontarians - MaRS
TORONTO, May 16, 2017 – An at-home sleep apnea test will be available to Ontario patients for the first time as the result of a unique MaRS program. BresoDx, a portable test for sleep apnea, is the first technology to complete MaRS EXCITE, an innovative initiative that accelerates the adoption of health technology in Ontario. … Read More
North American Businesses of Merck KGaA, Darmstadt, Germany Certified as 2017 Top Employer
and , Feb. 8, 2017 /CNW/ -- , a leading science and technology company which operates as EMD Serono, MilliporeSigma and EMD Performance Materials in and , today announced that its North American businesses have been certified by the Top Employers Institute for exceptional employee offerings.
Faculty of Medicine
We use machine learning to analyze sentences and figures in publications. We train the algorithm to read research papers like a scientist. This enabled us to automatically extract relevant figures from papers and decode the specific experimental contexts associated with each antibody use-cases.
Faculty of Medicine
It harnesses the exceptional expertise at U of T and its affiliated hospitals and fosters unique multidisciplinary collaborations to generate new discoveries in regenerative medicine. Through strategic investments and partnerships, it is also creating a pipeline from research to commercialization that will enable Canada to realize the full value of its research advances and bring them to the world.
SafeTEC™ Drug Safety Technology Consortium Organizes Validation Project of Cyclica’s Ligand Express™ Platform: Recruiting More Participants
Boston, MA (PRWEB) November 11, 2016 -- In a blinded study, members of the SafeTEC™ consortium, managed by One Million Solutions in Health, will evaluate the ability of Cyclica’s technologies to predict drug-protein interactions, and verify the Cyclica in silico results with industry-conducted in vitro experiments to achieve prospective validation.
Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (TSX-V: PRN) announced today that it has entered into an agreement with a syndicate of underwriters led by GMP Securities L.P.
Hydrogel Successfully Delivers Stem Cells to the Brain and Eye, Restoring Vision by 15%
Molly Shoichet, Canada Research Chair in Tissue Engineering at the University of Toronto, is a leader in the use of biomaterials to enhance cell delivery and to guide stem cell fate for tissue engineering, ...
KalGene gears up to manufacture and test promising Alzheimer's treatment with NRC, McGill and CIMTEC - Canada News Centre
KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer's treatment in Canada that the parties have been co-developing since 2015.